Chemohormonal regimen of epirubicin, etoposide, and dexamethasone in patients with hormone-refractory prostate cancer
2003
Abstract
Recent reports show that various chemotherapy regimens in combination with corticosteroids are effective options in the treatment of hormonally refractory carcinoma of the prostate (HRPC). We assessed retrospectively the efficiency and toxicity of chemo-hormonal regimen, consisting of epirubicin, etoposid and dexamethasone (EED) in patients with HRPC.
We treated 22 males who had stopped responding to hormonal therapy and antiandrogen withdrawal. A further part of the study describes the results of the treatment in detail.